COMIRNATY is the trade name for the Pfizer–BioNTech mRNA COVID-19 vaccine (BNT162b2), administered intramuscularly for prevention of COVID-19. It was one of the first widely authorized COVID-19 vaccines and has broad global marketing authorizations and prescription status in many jurisdictions. The platform uses mRNA vaccine technology.
Arbutus and Genevant filed three new lawsuits against Pfizer and BioNTech over mRNA vaccine lipid nanoparticle patents, shortly after receiving a $178 million payment from Moderna. Sanofi also launched two separate patent suits against Pfizer and Moderna. A Delaware court previously narrowed Moderna's defenses in a related case.
BioNTech enters May with first-quarter earnings due May 5 and a May 15 shareholder vote on a capital increase. The company is pushing its oncology pipeline as COVID-19 vaccine sales decline.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Pfizer is applying lessons from its Viagra launch to introduce its first obesity treatment, a monthly injection acquired from Metsera. The company aims to leverage past experience with sensitive health topics as it enters the competitive obesity market.
BioNTech filed a patent infringement lawsuit against Moderna in Delaware federal court, alleging the company's newly approved mNEXSPIKE vaccine uses proprietary mRNA technology without authorization.
BioNTech filed a patent infringement lawsuit against Moderna in Delaware federal court, alleging that Moderna's next-generation COVID-19 vaccine mNEXSPIKE violates its mRNA vaccine design patent.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05977127 |
Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly |
TERMINATED | PHASE2 |
| NCT05858450 |
This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times. |
COMPLETED | |
| NCT05781191 |
Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine |
COMPLETED | |
| NCT05396573 |
A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19 |
UNKNOWN | PHASE1 |
| NCT05394012 |
A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19 |
UNKNOWN | PHASE1 |
| NCT05378191 |
Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose |
UNKNOWN | PHASE2 |
| NCT05329220 |
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 |
COMPLETED | PHASE3 |
| NCT05329051 |
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years |
UNKNOWN | PHASE2 |
| NCT05323461 |
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines |
UNKNOWN | PHASE3 |
| NCT05239975 |
A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine |
WITHDRAWN | PHASE2 |
